companydirectorylist.com  Global Business Directories and Company Directories
Search Business,Company,Industry :


Country Lists
USA Company Directories
Canada Business Lists
Australia Business Directories
France Company Lists
Italy Company Lists
Spain Company Directories
Switzerland Business Lists
Austria Company Directories
Belgium Business Directories
Hong Kong Company Lists
China Business Lists
Taiwan Company Lists
United Arab Emirates Company Directories


Industry Catalogs
USA Industry Directories












Company Directories & Business Directories

KELDAR PARTNERS INC

OKOTOKS-Canada

Company Name:
Corporate Name:
KELDAR PARTNERS INC
Company Title:  
Company Description:  
Keywords to Search:  
Company Address: 15A Alberta Ave,OKOTOKS,AB,Canada 
ZIP Code:
Postal Code:
T7X 
Telephone Number: 7809625827 
Fax Number:  
Website:
 
Email:
 
USA SIC Code(Standard Industrial Classification Code):
103950 
USA SIC Description:
GENERATORS 
Number of Employees:
 
Sales Amount:
 
Credit History:
Credit Report:
 
Contact Person:
 
Remove my name



copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)









Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Your Subject:
Your Comment or Review:
Security Code:



Previous company profile:
KENJO CONSTRUCTION & RNVTN LTD
KENCAYD CONSULTING
KEMP CONSULTING LTD
Next company profile:
KEITH PONTIAC BUICK G M C LTD
KEITH PONTIAC BUICK GMC LTD
KALTHOFF, NEIL










Company News:
  • Semaglutide: Uses, Dosage, Side Effects, Brands - Drugs. com
    Semaglutide is a GLP-1 agonist used for weight loss, type 2 diabetes, and reducing cardiovascular and kidney risks by regulating appetite and blood sugar
  • Product warnings updated for GLP-1 RA class
    We have updated the product warnings for GLP-1 and dual GIP GLP-1 receptor agonists for two separate safety issues This relatively new and high-profile class of medicines is used to treat type 2 diabetes mellitus and or obesity
  • Semaglutide: Uses, Interactions, Mechanism of Action - DrugBank Online
    Semaglutide is a glucagon-like peptide 1 receptor agonist used to improve glycemic control in type 2 diabetes mellitus, treat obesity, and reduce the risk of major adverse cardiovascular events in selected adults
  • Semaglutide - Wikipedia
    Semaglutide is a glucagon-like peptide-1 receptor agonist [13][14][15] The drug decreases blood sugar levels The decrease is theorized to be caused by the mimicking of glucagon-like peptide-1 (GLP-1), an incretin [45]
  • Semaglutide: MedlinePlus Drug Information
    Semaglutide is in a class of medications called incretin mimetics It works by helping the pancreas to release the right amount of insulin when blood sugar levels are high
  • Semaglutide • LITFL
    Physiological implications: Semaglutide is a synthetic analog of human GLP-1, designed to resist degradation by DPP-4 enzyme, enhancing its half-life and efficacy
  • Semaglutide: Side effects, use for weight loss, cost
    Semaglutide belongs to the glucagon-like peptide-1 (GLP-1) receptor agonist drug class You’ll find key information about semaglutide below: Semaglutide is the active ingredient in the brand-name
  • Semaglutide: Diabetes Weight Loss Uses, Side Effects, Dosage
    Drug Class: Antidiabetics, Glucagon-like Peptide-1 Agonists What is semaglutide, and what is it used for? Semaglutide is a medication used in the treatment of type 2 diabetes mellitus and for chronic weight management, along with physical exercise, dietary restrictions, and lifestyle changes
  • TGA issues fresh warning for Ozempic and other high-profile drugs
    Australia's drugs regulator has issued a fresh warning for users of high-profile injectable diabetes and weight-loss drugs such as Ozempic




Business Directories,Company Directories
Business Directories,Company Directories copyright ©2005-2012 
disclaimer